UNICA IRIS Institutional Research Information System

CARTA, ANNAROSA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 158.468
NA - Nord America 7.949
AS - Asia 3.698
SA - Sud America 582
AF - Africa 119
OC - Oceania 38
Continente sconosciuto - Info sul continente non disponibili 6
Totale 170.860
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 156.338
US - Stati Uniti d'America 7.812
SG - Singapore 1.346
CN - Cina 1.321
UA - Ucraina 525
BR - Brasile 453
SE - Svezia 435
VN - Vietnam 285
DE - Germania 259
FI - Finlandia 230
GB - Regno Unito 227
FR - Francia 189
HK - Hong Kong 176
KR - Corea 108
IN - India 90
CA - Canada 89
AR - Argentina 47
ES - Italia 44
NL - Olanda 43
JP - Giappone 40
RU - Federazione Russa 39
BD - Bangladesh 36
IQ - Iraq 34
MX - Messico 30
AU - Australia 29
PL - Polonia 28
TR - Turchia 28
ZA - Sudafrica 28
IR - Iran 27
ID - Indonesia 25
CO - Colombia 20
PK - Pakistan 20
EC - Ecuador 19
EG - Egitto 19
UZ - Uzbekistan 19
AT - Austria 18
IE - Irlanda 17
BE - Belgio 16
IL - Israele 16
KE - Kenya 16
OM - Oman 15
VE - Venezuela 15
CL - Cile 14
SA - Arabia Saudita 14
MY - Malesia 12
PH - Filippine 12
MA - Marocco 10
TN - Tunisia 10
CY - Cipro 9
GH - Ghana 9
LT - Lituania 9
NZ - Nuova Zelanda 9
TH - Thailandia 9
AE - Emirati Arabi Uniti 8
JO - Giordania 8
CZ - Repubblica Ceca 7
DZ - Algeria 7
JM - Giamaica 7
AL - Albania 6
AZ - Azerbaigian 6
KZ - Kazakistan 6
NP - Nepal 6
ET - Etiopia 5
EU - Europa 5
GR - Grecia 5
PY - Paraguay 5
TT - Trinidad e Tobago 5
CH - Svizzera 4
HR - Croazia 4
MU - Mauritius 4
TW - Taiwan 4
UY - Uruguay 4
BO - Bolivia 3
CI - Costa d'Avorio 3
LB - Libano 3
PS - Palestinian Territory 3
PT - Portogallo 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
AM - Armenia 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
LI - Liechtenstein 2
LK - Sri Lanka 2
LU - Lussemburgo 2
RO - Romania 2
SV - El Salvador 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
EE - Estonia 1
GA - Gabon 1
GE - Georgia 1
GI - Gibilterra 1
GY - Guiana 1
HN - Honduras 1
HU - Ungheria 1
IS - Islanda 1
Totale 170.846
Salva come PNG Salva come JPEG
Città #
Cagliari 152.235
Uta 3.579
Fairfield 815
Singapore 739
Ashburn 603
Woodbridge 588
Chandler 496
San Jose 427
Houston 394
Seattle 351
Wilmington 341
Boardman 331
Ann Arbor 327
Dallas 316
Nyköping 291
Jacksonville 279
Cambridge 266
Beijing 263
Dearborn 207
Helsinki 136
Hong Kong 131
Los Angeles 119
Santa Clara 119
Shanghai 110
The Dalles 102
Nanjing 99
Hangzhou 94
Lauterbourg 94
Hefei 92
New York 91
Seoul 88
Ho Chi Minh City 87
Boston 85
Council Bluffs 72
San Diego 64
Hanoi 63
Buffalo 54
Milan 45
Guangzhou 42
Orem 41
Toronto 34
Nanchang 30
Shenyang 29
São Paulo 29
Changsha 28
Redwood City 28
Frankfurt am Main 27
London 27
Redondo Beach 26
Atlanta 24
Munich 24
Tokyo 24
Norwalk 23
Mountain View 22
Dong Ket 20
Hebei 20
Brooklyn 19
Chicago 19
Jinan 19
Tianjin 19
Sassari 18
Tashkent 18
Amsterdam 17
Montreal 17
Warsaw 17
Brussels 16
Jiaxing 16
Verona 16
Assèmini 15
Barcelona 15
Nuremberg 15
Phoenix 14
Rome 14
San Mateo 14
Belo Horizonte 13
Rio de Janeiro 13
Zhengzhou 13
Da Nang 12
Dublin 12
Johannesburg 12
Chennai 11
Nairobi 11
Orange 11
Poplar 11
Washington 11
Baghdad 10
Biên Hòa 10
Brasília 10
Haiphong 10
Pune 10
San Francisco 10
Stockholm 10
Vienna 10
Accra 9
Auburn Hills 9
Augusta 9
Cairo 9
Charlotte 9
Columbus 9
Curitiba 9
Totale 165.662
Salva come PNG Salva come JPEG
Nome #
Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease 5.334
Nematicidal activity of 2-thiophenecarboxaldehyde and methylisothiocyanate from caper (Capparis spinosa) against Meloidogyne incognita 4.621
null 4.110
Neuroprotective and anti-inflammatory properties of a novel non-thiazolidinedione PPARγ agonist in vitro and in MPTP-treated mice 3.826
Boosting phagocytosis and anti-inflammatory phenotype in microglia mediates neuroprotection by PPARγ agonist MDG548 in Parkinson's disease 3.695
The MPTP/probenecid model of progressive Parkinson's disease 3.511
Immunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson's disease 3.459
Role of Adenosine in the basal Ganglia 3.357
Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model. 3.251
PPAR-gamma agonist rosiglitazone inhibits TNF-alpha production by microglia and arrests nigrostriatal degeneration in a progressive Parkinson’s disease model. 3.163
A442 PPAR-gamma agonist rosiglitazone inhibits TNF-alpha production by microglia and arrests neurodegeneration in a progressive Parkinson´s disease model 3.011
Microglial phenotypes in Parkinson's disease and animal models of the disease 3.000
Trimethyl chitosan hydrogel nanoparticles for progesterone delivery in neurodegenerative disorders 2.972
Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function 2.940
Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy? 2.853
L-DOPA-induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role? 2.794
L dopa chronic treatment increases reactive microglia and tnf- alpha production in the 6-ohda lesioned striatum 2.706
Modulating microglia activity with PPAR-gamma agonists: a promising therapy for Parkinson's disease? 2.631
null 2.592
Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats 2.553
Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson’s disease 2.501
Disease modifying treatment with PPAR-gamma agonist rosiglitazone in a progressive mouse model of Parkinson's disease 2.488
Progressive Dopaminergic Degeneration in the Chronic MPTPp Mouse Model of Parkinson's Disease 2.421
Nicotine, cocaine, amphetamine, morphine, and ethanol increase norepinephrine output in the bed nucleus of stria terminalis of freely moving rats 2.281
PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease 2.235
Neuroprotection by the Immunomodulatory Drug Pomalidomide in the Drosophila LRRK2WD40 Genetic Model of Parkinson’s Disease 2.204
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression 2.096
PPAR-GAMMA RECEPTOR AGONIST PREVENTS NEURODEGENERATION AND BEHAVIOURAL DEFICITS IN A CHRONIC MPTP MOUSE MODEL OF PARKINSON’S DISEASE. 2.091
SELECTIVE CHANGES IN DENDRITIC SPINES OF STRIATAL MEDIUM SPINY NEURONS IN A CHRONIC MOUSE MODEL OF PARKINSON'S DISEASE. 1.996
The interrelationship between dopamine and noradrenaline in the prefrontal cortex: From physiology to therapy 1.995
The role of microglia–lymphocyte interaction in PD neuropathology 1.990
PROGRESSIVE DECLINE OF BEHAVIORAL AND BIOCHEMICAL PARAMETERS IN THE CHRONIC MPTP/PROBENECID MOUSE MODEL OF PARKINSON’S DISEASE. 1.945
PPAR-γ: Therapeutic Prospects in Parkinson's Disease. 1.895
PEROXIZOME-PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARG) AGONIST ROSIGLITAZONE COUNTERACTS BEHAVIORAL AND BIOCHEMICAL DEFICITS IN A CHRONIC 1-METHYL-4-PHENIL-1,2,3,4 TETRAHYDROPYRIDINE (MPTP) MOUSE MODEL OF PARKINSON’S DISEASE 1.867
Dyskinesia in Parkinson's disease therapy 1.867
null 1.857
Farmaci antiparkinsoniani ed attivi in altri disturbi motori 1.828
Advances in modelling alpha-synuclein-induced Parkinson's diseases in rodents: virus-based models versus inoculation of exogenous preformed toxic species 1.777
Microglial phagocytosis and its regulation: A therapeutic target in parkinson’s disease? 1.709
null 1.651
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat 1.649
Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson's Disease 1.612
Farmaci utilizzati nella terapia della Malattia di Parkinson e di altri disturbi motori 1.555
Beneficial effects of curtailing immune susceptibility in an Alzheimer's disease model 1.530
Controversie: Priming dopaminergico nel Parkinson. Il "priming" come modello sperimentale delle discinesie indotte da terapie dopaminergiche sostitutive nella Malattia di Parkinson 1.524
Can pioglitazone be potentially useful therapeutically in treating patients with Covid-19? 1.389
Long-term increase in GAD67 mRNA expression in the central amygdala of rats sensitized by drugs and stress 1.314
Adenosine signaling in the basal ganglia 1.301
Caffeine sensitization and cross-sensitization with amphetamine: association to post-synaptic changes in rat striatal neurons 1.246
Metabolomics fingerprint induced by the intranigral inoculation of exogenous human alpha-synuclein oligomers in a rat model of Parkinson’s disease 1.205
null 1.194
The 6-hydroxydopamine model of Parkinson's disease 1.186
Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease 1.176
Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats 1.176
The role of glia in Parkinson's disease: Emerging concepts and therapeutic applications 1.174
Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence 1.168
Modeling Parkinson’s disease neuropathology and symptoms by intranigral inoculation of preformed human α-synuclein oligomers 1.134
Dopamine and adenosine receptor interaction as the basis for the treatment of Parkinson's disease 1.121
null 1.108
Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease 1.076
Adenosine A2A receptors and Parkinson's disease 1.071
BDNF Alterations in Brain Areas and the Neurocircuitry Involved in the Antidepressant Effects of Ketamine in Animal Models, Suggest the Existence of a Primary Circuit of Depression 1.060
CAFFEINE SESITIZATION AND CROSS-SENSITIZATION WITH AMPHETAMINE: ASSOCIATION TO POST-SYNAPTIC CHANGES IN RAT STRIATAL NEURONS 1.051
CAFFEINE SENSITIZATION AND CROSS-SENSITIZATION WITH AMPHETAMINE: ASSOCIATION TO POST BUT NOT PRE-SYNAPTIC CHANGES IN RAT STRIATAL NEURON 1.043
The Intranigral Infusion of Human-Alpha Synuclein Oligomers Induces a Cognitive Impairment in Rats Associated with Changes in Neuronal Firing and Neuroinflammation in the Anterior Cingulate Cortex 1.016
null 1.012
null 981
Changes in the expression of tonic and phasic neurochemical markers of activity in a rat model of L-DOPA induced dyskinesia 977
Differential effect of MK 801 and scopolamine on c-fos expression induced by L-dopa in the striatum of 6-hydroxydopamine lesioned rats 967
Changes in the expression of tonic and phasic neurochemical markers of activity in a rat model of L-DOPA induced dynskinesia 955
Selective modifications in GAD67 mRNA levels in striatonigral and striatopallidal pathways correlate to dopamine agonist priming in 6-hydroxydopamine-lesioned rats 926
How reliable is the behavioural evaluation of dyskinesia in animal models of Parkinson's disease? 909
Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment 876
Alterations in GAD67, dynorphin and enkephalin mRNA in striatal output neurons following priming in the 6-OHDA model of Parkinson’s disease 837
null 830
Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous L-DOPA delivery in the 6-OHDA model of Parkinson's disease 814
Blockade of muscarinic receptors potentiates D1 dependent turning behavior and c-fos expression in 6-hydroxydopamine-lesioned rats but does not influence D2 mediated responses 811
null 801
Modulation of dopamine d1-mediated turning behavior and striatal c-fos expression by the substantia nigra 791
Modification of adenosine extracellular levels and adenosine A(2A) receptor mRNA by dopamine denervation 774
Effect of MK 801 on priming of D-1-dependent contralateral turning and its relationship to c-fos expression in the rat caudate-putamen 768
“Priming” to dopamine agonist-induced contralateral turning as model of non associative sensitization to the expression of the post-synaptic dopamine message 762
Role of prefrontal cortex dopamine and noradrenaline circuitry in addiction 736
MPTP: Advances from an Evergreen Neurotoxin 735
Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats 705
Cocaine effects on gene regulation in the striatum and behavior: increased sensitivity in D3 dopamine receptor-deficient mice 697
Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders 688
MPTP: advances from an evergreen neurotoxin 674
Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success? 674
Nanocrystals as an effective strategy to improve Pomalidomide bioavailability in rodent 663
GABA(A) receptors mediate orexin-A induced stimulation of food intake. 655
Changes in GAD67 and peptides mRNA levels in specific populations of striatal efferent neurons following priming with dopamine agonists in 6-OHDA lesioned rats 642
Lack of a role for the D3 receptor in clozapine induction of c-fos demonstrated in D3 dopamine receptor-deficient mice 634
Alterazioni nei livelli striatali di RNAm della GAD67, dinorfina e enkefalina, in seguito a priming con agonisti dopaminergici nel modello di morbo di parkinson della 6-ohda 629
Expression offunctional leptin receptors in rodent leydig cells 612
Differential effect of priming with dopamine agonists on mrna for GAD-67, dynorphin and enkephalin in 6-OHDA lesioned rats 611
Combined measure of salivary alpha-synuclein species as diagnostic biomarker for Parkinson's disease 608
Different patterns of behavior and gene expression induced by chronic L-DOPA and A2A antagonists plus L-DOPA treatments in 6-hydroxydopamine lesioned rats 604
Blockade of A2A receptors plus L-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from L-DOPA alone in the rat globus pallidus and substantia nigra reticulata 600
EEG modifications in the cortex and striatum after dopaminergic priming in the 6-hydroxydopamine rat model of Parkinson's disease 555
Totale 164.665
Salva come PNG Salva come JPEG
Categoria #
all - tutte 212.803
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 212.803
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215.043 0 0 0 0 0 0 0 0 0 1.926 1.735 1.382
2021/20228.062 1.090 465 470 646 618 417 493 409 759 912 869 914
2022/202314.219 1.057 1.774 1.717 1.115 966 1.524 863 1.000 1.004 1.130 1.452 617
2023/202413.719 605 638 656 772 1.377 2.227 2.265 999 562 976 1.216 1.426
2024/202520.375 2.774 3.665 4.834 2.900 1.350 1.690 1.859 175 258 249 256 365
2025/20266.592 461 274 760 574 479 581 1.680 494 514 775 0 0
Totale 171.191